Literature DB >> 20085392

Access with evidence development in the UK: past experience, current initiatives and future potential.

Andrew Briggs1, Karen Ritchie, Elisabeth Fenwick, Kalipso Chalkidou, Peter Littlejohns.   

Abstract

Access with evidence development (AED) describes the general approach of linking some form of access to the healthcare market with the generation of additional evidence relating to the value of the healthcare intervention under evaluation, with an explicit aim of aiding future decision making. A number of health systems around the world are interested in the potential for such schemes. This article looks in detail at the potential for some form of AED in the UK, focusing on the two major decision-making bodies: the Scottish Medicines Consortium in Scotland and the National Institute for Health and Clinical Excellence in England and Wales. We consider past experience with these approaches and current initiatives that are exploring their potential, and speculate as to how these schemes might develop in the future.

Mesh:

Year:  2010        PMID: 20085392     DOI: 10.2165/11531410-000000000-00000

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  14 in total

1.  Coverage options for promising technologies: Medicare's 'coverage with evidence development'.

Authors:  Sean R Tunis; Steven D Pearson
Journal:  Health Aff (Millwood)       Date:  2006 Sep-Oct       Impact factor: 6.301

2.  Medicare's requirement for research participation as a condition of coverage: is it ethical?

Authors:  Steven D Pearson; Franklin G Miller; Ezekiel J Emanuel
Journal:  JAMA       Date:  2006-08-23       Impact factor: 56.272

3.  Establishing a comprehensive continuum from an evidentiary base to policy development for health technologies: the Ontario experience.

Authors:  Leslie Levin; Ron Goeree; Nancy Sikich; Birthe Jorgensen; Melissa C Brouwers; Tony Easty; Catherine Zahn
Journal:  Int J Technol Assess Health Care       Date:  2007       Impact factor: 2.188

4.  Making a decision to wait for more evidence: when the National Institute for Health and Clinical Excellence recommends a technology only in the context of research.

Authors:  Kalipso Chalkidou; Andrew Hoy; Peter Littlejohns
Journal:  J R Soc Med       Date:  2007-10       Impact factor: 5.344

5.  Addressing uncertainties about the effects of treatments offered to NHS patients: whose responsibility?

Authors:  Iain Chalmers
Journal:  J R Soc Med       Date:  2007-10       Impact factor: 5.344

6.  Coverage with evidence development: an examination of conceptual and policy issues.

Authors:  John Hutton; Paul Trueman; Christopher Henshall
Journal:  Int J Technol Assess Health Care       Date:  2007       Impact factor: 2.188

7.  Proposed changes for nurse education in England (UK) as a result of the Darzi report (DoH, 2008a) Health Quality Care for All--NHS next stage review final report: some initial observations.

Authors:  Karen Holland
Journal:  Nurse Educ Pract       Date:  2008-09       Impact factor: 2.281

8.  Evidence-based decision making: when should we wait for more information?

Authors:  Kalipso Chalkidou; Joanne Lord; Alastair Fischer; Peter Littlejohns
Journal:  Health Aff (Millwood)       Date:  2008 Nov-Dec       Impact factor: 6.301

9.  The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden.

Authors:  S Dewilde; F Turk; M Tambour; T Sandström
Journal:  Curr Med Res Opin       Date:  2006-09       Impact factor: 2.580

10.  Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.

Authors:  M Humbert; R Beasley; J Ayres; R Slavin; J Hébert; J Bousquet; K-M Beeh; S Ramos; G W Canonica; S Hedgecock; H Fox; M Blogg; K Surrey
Journal:  Allergy       Date:  2005-03       Impact factor: 13.146

View more
  11 in total

1.  Role of centralized review processes for making reimbursement decisions on new health technologies in Europe.

Authors:  Tania Stafinski; Devidas Menon; Caroline Davis; Christopher McCabe
Journal:  Clinicoecon Outcomes Res       Date:  2011-08-30

2.  Translating comparative effectiveness research into clinical practice: the UK experience.

Authors:  Tom Walley
Journal:  Drugs       Date:  2012-01-22       Impact factor: 9.546

3.  When to wait for more evidence? Real options analysis in proton therapy.

Authors:  Janneke P C Grutters; Keith R Abrams; Dirk de Ruysscher; Madelon Pijls-Johannesma; Hans J M Peters; Eric Beutner; Philippe Lambin; Manuela A Joore
Journal:  Oncologist       Date:  2011-12-06

4.  Coping with uncertainty on health decisions: assessing new solutions.

Authors:  Fernando Antoñanzas; Roberto Rodríguez-Ibeas; Carmelo A Juárez-Castelló
Journal:  Eur J Health Econ       Date:  2012-08

5.  Single technology appraisal at the UK National Institute for Health and clinical excellence: a source of evidence and analysis for decision making internationally.

Authors:  Mark Sculpher
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

6.  Access with evidence development: the US experience.

Authors:  Penny E Mohr; Sean R Tunis
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

7.  Principles of design of access with evidence development approaches: a consensus statement from the Banff Summit.

Authors:  Devidas Menon; Christopher J McCabe; Tania Stafinski; Richard Edlin
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

8.  We know accurately only when we know little.

Authors:  Stuart MacLeod; Craig Mitton
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

Review 9.  Acknowledging patient heterogeneity in economic evaluation : a systematic literature review.

Authors:  Janneke P C Grutters; Mark Sculpher; Andrew H Briggs; Johan L Severens; Math J Candel; James E Stahl; Dirk De Ruysscher; Albert Boer; Bram L T Ramaekers; Manuela A Joore
Journal:  Pharmacoeconomics       Date:  2013-02       Impact factor: 4.981

Review 10.  Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers.

Authors:  Jakub Adamski; Brian Godman; Gabriella Ofierska-Sujkowska; Bogusława Osińska; Harald Herholz; Kamila Wendykowska; Ott Laius; Saira Jan; Catherine Sermet; Corrine Zara; Marija Kalaba; Roland Gustafsson; Kristina Garuolienè; Alan Haycox; Silvio Garattini; Lars L Gustafsson
Journal:  BMC Health Serv Res       Date:  2010-06-07       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.